Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma giant gains control over Coley’s Toll-like receptor patent estate and next-generation vaccine adjuvants with $164 million acquisition.